Co-Aleva Drug Interactions

The interaction of Ebastine in combination with either ketoconazole or erythromycin (both known to prolong the QTc interval) has been evaluated. Interaction has been observed with these combinations, resulting in higher Ebastine plasma levels but only in about a 10 msec increase in QTc greater than the increase seen with ketoconazole or erythromycin alone.
When Ebastine is administered with food, there is a 1.5 to 2.0 fold increase in the plasma levels and the AUC of the main active acid metabolite of Ebastine. This increase does not alter the T_max. The administration of Ebastine with food does not cause a modification in its clinical effect.
Concurrent use of barbiturates, carbamazepine, phenytoin, primidone or rifampicin may enhance the metabolism and reduce the effects of systemic corticosteroids. Conversely oral contraceptives or ritonavir may increase plasma concentrations of corticosteroids. Use of corticosteroids with potassium-depleting diuretics, such as thiazides and furosemide may cause excessive potassium loss. There is also an increased risk of hypokalemia with concurrent amphotericin B or bronchodilator therapy with xanthines or beta 2-agonists. There may be increased incidence of gastrointestinal bleeding and ulceration when corticosteroids are given with NSAIDs. Response to anticoagulants may be altered by corticosteroids and requirements of antidiabetic drugs and antihypertensives may be increased. Corticosteroids may decrease serum concentrations of salicylates and may decrease the effect of antimuscarinics in myasthenia gravis.